CoChat
Sign Up
Cited by 322Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsAdvanced Radiotherapy Techniques

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Delker, Andreas, Fendler, Wolfgang Peter, Kratochwil, Clemens, Brunegraf, Anika, Gosewisch, Astrid, Gildehaus, Franz Josef, Tritschler, Stefan, Stief, Christian Georg, Kopka, Klaus, Haberkorn, Uwe, Bartenstein, Peter, Böning, Guido·2016·European Journal of Nuclear Medicine and Molecular Imaging
DOI 10.1007/s00259-015-3174-7
Open this paper in CoChat — free account

Abstract

Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand (177)Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.Methods Whole-body planar images and SPECT/CT images of the abdomen were acquired in five patients (mean age 68 years) for during two treatment cycles at approximately 1, 24, 48 and 72 h after administration of 3.6 GBq (range 3.4 to 3.9 GBq) (177)Lu-DKFZ-PSMA-617. Quantitative 3D SPECT OSEM reconstruction was performed with corrections for photon scatter, photon attenuation and detector blurring. A camera-specific calibration factor derived from phantom measurements was used for quantitation. Absorbed doses were calculated for various organs from the images using a combination of linear approximation, exponential fit, and target-specific S values, in accordance with the MIRD scheme. Absorbed doses to bone marrow were estimated from planar and SPECT images and with consideration of the blood sampling method according to the EANM guidelines.Results The average (± SD) absorbed doses per cycle were 2.2 ± 0.6 Gy for the kidneys (0.6 Gy/GBq), 5.1 ± 1.8 Gy for the salivary glands (1.4 Gy/GBq), 0.4 ± 0.2 Gy for the liver (0.1 Gy/GBq), 0.4 ± 0.1 Gy for the spleen (0.1 Gy/GBq), and 44 ± 19 mGy for the bone marrow (0.012 Gy/GBq). The organ absorbed doses did not differ significantly between cycles. The critical absorbed dose reported for the kidneys (23 Gy) was not reached in any patient. At 24 h there was increased uptake in the colon with 50 - 70 % overlap to the kidneys on planar images. Absorbed doses for tumour lesions ranged between 1.2 and 47.5 Gy (13.1 Gy/GBq) per cycle.Conclusion The salivary glands and kidneys showed high, but not critical, absorbed doses after RLT with (177)Lu-DKFZ-PSMA-617. We suggest that (177)Lu-DKFZ-PSMA-617 is suitable for radiotherapy, offering tumour-to-kidney ratios comparable to those with RLT agents currently available for the treatment of neuroendocrine tumours. Our dosimetry results suggest that (177)Lu-DKFZ-PSMA-617 treatment with higher activities and more cycles is possible without the risk of damaging the kidneys.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-015-3174-7

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Siegel J, Wessels B, Watson E, Stabin M, Vriesendorp H, Bradley E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm. 1990;3:213–34.

Cited by

Sorted by citations

See all 322

Related

Metadata

Authors
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., Bartenstein, P., & Böning, G.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • University Hospital Heidelberg (DE)
  • German Cancer Research Center (DE)
Corresponding author
Böning, Guido
ORCID
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Publisher
Springer Science and Business Media LLC
Published
2015-08-29
Volume
43
Issue
1
Pages
42-51
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
DOI
10.1007/s00259-015-3174-7
OpenAlex
W1140456871
Cited by
322
References
42
Citations by year
2026: 16 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 31 · 2021: 51 · 2020: 41 · 2019: 33 · 2018: 32 · 2017: 27 · 2016: 26 · 2015: 1
FWCI
23.21
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutschen Konsortium für Translationale Krebsforschung
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
Keywords
radioligand therapy, dosimetry, absorbed dose, metastatic prostate cancer, PSMA ligands, SPECT/CT, kidney dose, salivary gland dose, bone marrow dose, critical organ dose, tumor dose, EANM guidelines
MeSH terms
Aged, Aged, 80 and over, Antigens, Surface, Humans, Male, Middle Aged, Neoplasm Metastasis, Organometallic Compounds, Peptides, Radiometry, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review